Подход к поиску продуцентов антибиотиков, преодолевающих лекарственную устойчивость микроорганизмов

В настоящее время проблема устойчивости к антибиотикам оппортунистических и патогенных микроорганизмов является чрезвычайно актуальной. Чтобы найти новые эффективные природные антибиотики, необходимо активизировать процесс поиска. При поэтапном отборе наиболее перспективных продуцентов нами была введена стадия определения антибиотической активности культуральной жидкости исследуемых природных штаммов в отношении клинических изолятов госпитальных микроорганизмов с множественной устойчивостью к антибиотикам медицинского назначения. Определение видовой принадлежности потенциальных продуцентов позволяет выбрать тех продуцентов конкретного вида, которые отличаются по антимикробному спектру активности от описанных в литературе. Были отобраны четыре штамма актиномицетов, которые проявляли активность в отношении устойчивых клинических изолятов дрожжей Candida albicans, C.famata, C. arapsilosis и Cryptococcus neoformans, а именно: Nocardia soli ИНА 01217, Streptomyces bottropensis ИНА 01214, S.chromofuscus ИНА 01211 и S.netropsis ИНА 01190. Штамм N.soli ИНА 01217 также проявляет антибиотическую активность против грамотрицательной бактерии Escherichia coli ATCC 25922. Эти штаммы продуцентов актиномицетов были отобраны для последующих химических исследований образованных ими противомикробных соединений.

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available online: http://www.cdc.gov/drugresistance/threat-report-2013.

2. O’Neill J. The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final report and recommendations, 2016. Available online: http://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf.

3. Berdy J. Thoughts and facts about antibiotics: Where we are now and where we are heading. J Antibiot. 2012; 65: 385–395.

4. Ефименко Т.А.; Терехова Л.П.; Ефременкова O.В. Современное состояние проблемы антибиотикорезистентности патогенных бактерий. Анибиотики и химиотер. 2019; 64: 5–6, 64–68.

5. Glukhova A.A., Karabanova A.A., Yakushev A.V., Semenyuk I.I., Boykova Y.V., Malkina N.D., Efimenko T.A., Ivankova T.D., Terekhova L.P., Efremenkova O.V. Antibiotic Activity of Actinobacteria from Digestive Tract of Millipede Nedyopus dawydoffiae (Diplopoda). Antibiotics (Basel). 2018; 7: 4: 94. doi: 10.3390/antibiotics7040094.

6. Valagurova E.V., Kozyritskaya V.E., Iutinskaya G.A. Actinomycetes of Streptomyces genus. (in Russian) Publisher «Scientific Book»: Kiev, Ukraine, 2003; 1–645.

7. Goodfellow M., Kämpfer P., Busse H.-J., Suzuki K., Ludwig W., Whitman W.B. (eds.). Bergey’s manual of systematic bacteriology, 2 nd ed.; Springer-Verlag, New York, USA; 2012; 5: A: 376–419, 1455–1768.

8. Demiankova M.V., Kalashnikova E.A., Glukhova A.A., Ivankova T.D., Terekhova L.P., Boykova Y.V., Efimenko T.A., Efremenkova O.V. Activity of the strain Streptomyces hydrogenans against phytopathogenic fungi. Open Acc J Envi Soi Sci (OAJESS). 2018; 1: 5:103–105, doi:10.32474/OA-JESS.2018.01.000121.

9. Brown M.S., Akopiants K., Resceck D.M., McArthur H.A.I., McCormick E., Reynolds K.A. Biosynthetic Origins of the natural product, thiolactomycin: A unique and selective inhibitor of type II dissociated fatty acid synthases. J Am Chem Soc. 2003; 125 (34): 10166–10167. doi: 10.1021/ja034540i.

10. Fulmer T. Fatty acid synthase II (FASII) pathway. Science-Business eXchange 2009, 2, 11, 430–430. doi: 10.1038/scibx.2009.430.

11. Tatsuta K., Gunji H., Tajima S., Ishiyama T., Imai S., Okuyama S., Fukatsu S. Biosynthetic studies on oleandomycin by incorporation of the chemically synthesized aglycones. J Antibiot. 1990; 43: 909–911. doi: 10.7164/antibiotics.43.909.

12. Vilches C., Hernandez C., Mendez C., Salas J.A. Role of glycosylation and deglycosylation in biosynthesis of and resistance to oleandomycin in the producer organism, Streptomyces antibioticus. J Bact. 1992; 174: 1: 161–165. doi: 10.1128/jb.174.1.161-165.1992.

13. Schimana J., Fiedler H.-P., Groth I., Submuth R., Beil W., Walker M., Zeeck A. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot. 2000; 53 (8): 779–787. doi: 10.7164/antibiotics.53.779.

14. Hollstein U. Actinomycin. Chemistry and mechanism of action. Chem Rev. 1974; 74 (6): 625–652. doi: 10.1021/cr60292a002.

15. Hütter R., Keller-Schierlein W., Knüsel F., Prelog V., Rodgers G. C. The metabolic products of microorganisms. Boromycin. Helvetica Chimica Acta. 1967; 50 (6): 1533–1539

16. Waisvisz J.M., van der Hoeven M.G., van Peppen J., Zwennis W.C.M. Bottromycin. I. A new sulfur-containing antibiotic. J Am Chem Soc. 1957; 79 (16): 4520–4521. doi: 10.1021/ja01573a072.

17. Yamazaki M., Yamashita T., Harada T., Nishikiori T., Saito S., Shimada N., Fujii A. 44-Homooligomycins A and B, new anti-tumor antibiotics from Streptomyces bottropensis producing organisms, fermentation, isolation, structure elucidation and biological properties. J Antibiot. 1992; 45 (2): 171–179. doi: 10.7164/antibiotics.45.171.

18. Leach B.E., Calhoun K.M., Johnson LeRoy E., Teeters C.M., Jackson W.G. Char-treusin, a new antibiotic produced by Streptomyces chartreusis, a new species. J Am Chem Soc. 1953; 75 (16): 4011–4012. doi: 10.1021/ja01112a040.

19. Wu Q., Liang J., Lin S., Zhou X., Bai L., Deng Z., Wang Z. Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin (A23187) in Streptomyces chartreusis NRRL 3882. Antim Agent Chem. 2011; 55 (3): 974–982. doi: 10.1128/AAC.01130-10.

20. Miller-Wideman M., Makkar N., Tran M., Isaac B., Biest N., Stonard R. Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992; 45 (6): 914–921. doi: 10.7164/antibiotics.45.914.

21. Fujiwara A., Tazoe M., Hoshino T., Sekine Y., Fujiwara M. Structural studies of an antracyclinone antibiotic SM-173B produced by Streptomyces chromofuscus SM-173. Symposium on the Chemistry of Natural Products, symposium papers. 1979; 22: Abstr. No. 59: 448–455.

22. Akiko F., Mitsuhiko F., Tatsuo H., Yuzuru S., Masaaki T. Antibiotic SM-173B. Patent US 4206129, June 3, 1980.

23. Kulkarni M., Gorthi S., Banerjee G., Chattopadhyay P. Production, characterization and optimization of actinomycin D from Streptomyces hydrogenans IB310, an antagonistic bacterium against phytopathogens. Biocatalysis and Agricultural Biotechnology, 2017, 10, 69-74. doi: 10.1016/j.bcab.2017.02.009.

24. Hayashi T., Noto T., Nawata Y., Okazaki H., Sawada M., Ando K. Cyanocycline A, a new antibiotic. Taxonomy of the producing organism, fermentation, isolation and characterization. J Antibiot (Tokyo). 1982; 35 (7): 771–777. doi: 10.7164/antibiotics.35.771.

25. Gould S.J., He W., Cone M.C. New cyanocyclines from a cyanide-treated broth of Streptomyces lusitanus. J Nat Prod. 1993; 56 (8): 1239–1245. doi:10.1021/np50098a006.

26. Kluepfel D., Baker H. A., Piattoni G., Sehgal S. N., Sidorowicz A., Singh K., Vezina C. Naphthyridinomycin, a new broad-spectrum antibiotic. J Antibiot (Tokyo). 1975; 28 (7): 497–502. doi: 10.7164/antibiotics.28.497.

27. Villax I. Process of fermentation of chlortetracycline and tetracycline antibiotics. Patent US 3401088 A. Sept., 10, 1968.

28. Han Z., Xu Y., McConnell O., Liu L., Li Y., Qi S., Huang X., Qian P. Two antimycin a analogues from marine-derived actinomycete Streptomyces lusitanus. Mar Drugs. 2012; 10 (3): 668–676. doi: 10.3390/md10030668.

29. Finlay A.C., Hochstein F.A., Sobin B.A., Murphy F.X. Netropsin, a New antibiotic produced by a Streptomyces. J Am Chem Soc. 1951; 73 (1): 341–343. doi: 10.1021/ja01145a113.

30. Arcamone F., Cassinelli G., Fantini G., Grein A., Orezzi P., Pol C., Spalla C. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S.peucetius var. caesius. Biothecnology and Bioengineering, 1969; 11 (6) 1101–1110. doi: 10.1002/bit.260110607.

31. Grein A., Spalla C., Di Marco A., Canevazzi G. Descrizione e classificazione di un attinomiceti (Streptomyces peucetius sp. nova) produttore di una sostanza attivita antitumorale: La daunomicina. (in Italian) G Microbiol. 1963; 11: 109–118.

32. Guilfoile P.G., Hutchinson C.R. A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. PNAS. 1991; 88 (19): 8553–8557. doi: 10.1073/pnas.88.19.8553.

33. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! Clin Infect Dis. 2009; 48 (1): 1–12. doi: 10.1086/595011.

34. Tacconelli E., Magrini N., World Health Organisation. 2017, Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available on line: https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25FebET_NM_WHO.pdf

35. Beardsley J., Halliday C.L., Chen S.C-A, Sorrell T.C. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. Future Microbiol. 2018, 13, 10, 1175–1191. doi:10.2217/fmb-2018-0059.

36. Fisher M.C., Hawkins N.J., Sanglard D., Gurr S.J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018; 360 (6390): 739–742. doi: 10.1126/science.aap7999.

37. Butler M.S., Cooper M.A. Antibiotics in the clinical pipeline in 2011. J Antibiot. 2011; 64 (6): 413–425. doi: 10.1038/ja.2011.44.

38. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013; 66 (10): 571–591. doi: 10.1038/ja.2013.86.

39. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot. 2017; 70 (1): 3–24. doi:10.1038/ja.2016.72.

40. Berdy J. Bioactive microbial metabolites. J Antibiot. 2005; 58 (1): 1–26. doi: 10.1038/ja.2005.

41. Baltz R.H. Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J Ind Microbiol Biotechnol. 2006; 33 (7): 507–513. doi: 10.1007/s10295-005-0077-9.